| Compound | Disease | Phase |
|---|---|---|
| Rodatristat ethyl | Pulmonary Arterial Hypertension (PAH) | Phase 2 |
| Idiopathic Pulmonary Fibrosis (IPF) | Research | |
| Sarcoidosis | Research | |
| ALTA-2530 | Bronchiolitis Obliterans Syndrome | IND Enabling |
| Next-Generation TPH Inhibitors | Oral agents for multiple indications | Research |
| Alternative routes of administration for multiple indications | Research |
| Compound | Disease | Research | IND Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| Rodatristat Ethyl | Pulmonary Arterial Hypertension (PAH) | PAH STUDY NOW ENROLLING | ||||
| Idiopathic Pulmonary Fibrosis (IPF) | ||||||
| ALTA-2530 | Transplant-associated bronchiolitis obliterans syndrome | |||||
| Chemical-induced bronchiolitis obliterans syndrome | * Partnered with BARDA / NIAID | |||||
| Next-Generation TPH Inhibitors | Oral agents for multiple indications | |||||
| Alternative routes of administration of multiple indications | ||||||
